Updated: eribulin versus taxanes with trastuzumab-pertuzumab for first-line advanced breast cancer
A new analysis of the Japanese JBCRG-M06/EMERALD trial is sharpening the debate over how best to deliver first-line therapy for ...
A new analysis of the Japanese JBCRG-M06/EMERALD trial is sharpening the debate over how best to deliver first-line therapy for ...
A new clinical study is drawing attention to the possibility of treating HER2-positive breast cancer before surgery with a next-generation ...
In the relentless battle against HER2-positive breast cancer, a groundbreaking breakthrough is emerging from the cutting-edge intersection of radiopharmaceuticals and ...
In a groundbreaking study published in BMC Health Services Research, researchers Lochid-amnuay and Kongsakon delve into the cost-utility and budget ...
A groundbreaking development in the treatment of HER2-positive breast cancer has emerged, heralding a new era in radioimmunotherapy that promises ...
In a groundbreaking advancement for oncology, a recent study has shed new light on treatment strategies for older patients with ...
In a groundbreaking development presented at the ESMO Congress 2025, the oncology field witnesses a transformative leap forward with the ...
In the rapidly evolving realm of oncology, understanding the mechanisms that confer drug resistance remains one of the most formidable ...
Metformin, a drug primarily prescribed to manage type 2 diabetes, has increasingly captured the attention of oncologists and cancer researchers ...
In the relentless battle against HER2-positive breast cancer, trastuzumab (commonly known by its brand name, Herceptin) has long stood as ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine